Evidence map›Paper›PMID 23663325›Full record

ArticleItalian journal of pediatrics2013

Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression.

Sonia Carta, Michela Silvestri, Giovanni A Rossi

Open access · goldAbstract read
In one paragraph

Article in Italian journal of pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. From Legacy to Innovation: Pidotimod's Expanding Therapeutic Horizon.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  6. Mpox (formerly monkeypox): pathogenesis, prevention, and treatment.Signal transduction and targeted therapy · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.Mediterranean journal of hematology and infectious diseases · 2020
    Article
  11. Article
  12. Immunostimulants in respiratory diseases: focus on Pidotimod.Multidisciplinary respiratory medicine · 2019
    Review
  13. Review
  14. Pidotimod: the state of art.Clinical and molecular allergy : CMA · 2015
    Article
  15. Pidotimod: the past and the present.Italian journal of pediatrics · 2013
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sonia CartaPediatric Allergy and Pulmonary Disease Unit, Istituto Giannina Gaslini, Via G Gaslini 5, Genoa, Italy.
Michela Silvestri
Giovanni A Rossi
Istituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent respiratory infections are one of the most important causes of morbidity in childhood. When immune functions are still largely immature, the airway epithelium plays a primary defensive role since, besides providing a physical barrier, it is also involved in the innate and the adaptive immune responses. A study was therefore designed to evaluate in vitro whether pidotimod, a synthetic dipeptide able to stimulate the inflammatory and immune effector cells, could activate bronchial epithelial cell functions involved in response to infections.

methodsBEAS-2B cell line (human bronchial epithelial cells infected with a replication-defective Adenovirus 12-SV40 virus hybrid) were cultured in the presence of pidotimod, with or without tumor necrosis factor (TNF)-α or zymosan to assess: a) intercellular adhesion molecule (ICAM)-1 expression, by flow cytometry; b) toll-like receptor (TLR)-2 expression and production, by immunofluorescence flow cytometry and western blotting; d) interleukin (IL)-8 release, by enzyme-linked immunosorbent assay (ELISA); e) activated extracellular-signal-regulated kinase (ERK1/2) phosphorylation and nuclear factor-kappa B (NF-kB) activation, by western blotting.

resultsThe constitutive expression of ICAM-1 and IL-8 release were significant up-regulated by TNF-α (ICAM-1) and by TNF-α and zymosan (IL-8), but not by pidotimod. In contrast, an increased TLR-2 expression was found after exposure to pidotimod 10 and 100 μg/ml (p < 0.05) and to the association pidotimod 100 μg/ml + TNF-α (p < 0.05). Western blot analysis substantiated that the constitutive TLR-2 expression was significantly increased after exposure to all the stimuli. Finally, while a remarkable inhibition of TNF-α -induced ERK1/2 phosphorylation was observed in the presence of pidotimod, both TNF-α and pidotimod were effective in inducing NF-kB protein expression in the cytoplasm and its nuclear translocation.

conclusionThrough different effects on ERK1/2 and NF-kB, pidotimod was able to increase the expression of TLR-2 proteins, surface molecules involved in the initiation of the innate response to infectious stimuli. The lack of effect on ICAM-1 expression, the receptor for rhinovirus, and on IL-8 release, the potent chemotactic factor for neutrophils (that are already present in sites of infection), may represent protective functions. If confirmed in vivo, these activities may, at least in part, clarify the mechanism of action of this molecule at airway level.

Indexed as

BiomarkersBlotting, WesternBronchiCell LineCell NucleusEnzyme-Linked Immunosorbent AssayEpithelial CellsFlow CytometryGene Expression RegulationHumansImmunologic FactorsIntercellular Adhesion Molecule-1Interleukin-8MAP Kinase Signaling SystemNF-kappa BPhosphorylationBiomarkersICAM1 protein, humanImmunologic FactorsIntercellular Adhesion Molecule-1Interleukin-8NF-kappa BpidotimodPyrrolidonecarboxylic AcidThiazolidinesTLR2 protein, humanToll-Like Receptor 2Tumor Necrosis Factor-alpha

Identifiers

PMID23663325
PMCPMC3733658
OpenAlexW2163314509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.